PCSC Shareholders Clear Final Hurdle, Approving SPAC Merger with Freenome

summarizeSummary

On July 15, 2026, PCSC shareholders approved all proposals for the SPAC merger with Freenome, clearing the path for the deal to close. The vote was decisive, with over 87% of votes cast in favor of the business combination.

check_boxKey Events · M&A and Partnerships · PCSC

• Shareholders Approve Freenome Merger

  The Business Combination Proposal passed with 6,819,879 votes for (87.4% of votes cast), against 980,832, with 1,000 abstentions. All other related proposals, including domestication and equity plans, also received strong approval.

• Deal Closing Now Imminent

  With shareholder approval secured, the merger can close, combining PCSC with Freenome and its best-in-class colorectal cancer screening test. The transaction includes a $240 million PIPE, providing critical funding.

• Vote Follows Strong Clinical Data

  The approval comes just days after Freenome's SimpleScreen CRC v2 showed best-in-class detection of precancerous lesions in a pivotal study, strengthening the merger's strategic rationale.

• Going Concern Risk Addressed

  PCSC's recent 10-Q disclosed a going concern warning and only $437,369 in cash. The merger's completion is essential to resolve this financial distress and fund operations.

auto_awesomeAnalysis · PCSC · Industrial Applications And Services

Shareholders of Perceptive Capital Solutions Corp voted overwhelmingly to approve the merger with Freenome, removing the last major uncertainty for the deal. With the vote secured, the combined company can now close the transaction, gaining access to Freenome's best-in-class colorectal cancer screening test and the $240 million PIPE financing. This approval comes just days after Freenome released compelling clinical data and amid PCSC's own going concern warning, making the merger's completion critical for the company's survival and future value.